Mind Medicine (MindMed) (NASDAQ: MNMD – Get Rating) is one of 49 corporations in the “Medicines and Botanicals” sector, but how does it weigh against its rivals? We will compare Mind Medicine (MindMed) with related companies based on its dividend strength, valuation, risk, institutional ownership, analyst recommendations, profitability and earnings.
This table compares Mind Medicine (MindMed) and the net margins, return on equity and return on assets of its rivals.
|Net margins||Return on equity||Return on assets|
|Mind Medicine (MindMed)||N / A||-55.27%||-51.10%|
|Mind Medicine (MindMed) competitors.||-179.08%||-256.98%||-16.14%|
This is a breakdown of the current ratings and recommendations for Mind Medicine (MindMed) and its rivals, as reported by MarketBeat.com.
|Sell ratings||Keep the ratings||Buy ratings||Strong purchase ratings||Evaluation score|
|Mind Medicine (MindMed)||0||0||2||0||3.00|
|Mind Medicine (MindMed) competitors.||270||674||673||27||2.28|
Mind Medicine (MindMed) currently has a consensus price target of 8.00, indicating a potential upside of 900.00%. As a group, the Medicines and Botanicals companies have a potential upside of 109.47%. Given Mind Medicine (MindMed) strongest consensus score and possible higher upside, research analysts clearly believe Mind Medicine (MindMed) is more supportive than its rivals.
Insider and institutional ownership
10.8% of Mind Medicine (MindMed) shares are owned by institutional investors. By comparison, 16.3% of the shares of all Medicinals & Botanics companies are owned by institutional investors. 23.1% of the shares of all “Medicines and Botanicals” companies are owned by insiders. Strong institutional ownership indicates that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Evaluation and earnings
This table compares Mind Medicine (MindMed) and its rivals in terms of revenue, earnings per share (EPS) and valuation.
|Gross Income||Net income||Price / earnings ratio|
|Mind Medicine (MindMed)||N / A||– $ 93.04 million||-3.48|
|Mind Medicine (MindMed) competitors.||$ 238.89 million||– $ 88.70 million||-7.78|
Mind Medicine (MindMed) rivals have higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Mind Medicine (MindMed) rivals beat Mind Medicine (MindMed) on 6 of the 11 factors compared.
Mind Medicine Company Profile (MindMed). (Get evaluation)
Mind Medicine (MindMed) Inc., a clinical-stage biopharmaceutical company, develops new products to treat brain health disorders related to psychiatry, addiction, pain and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, a nicotinic a3ß4 cholinergic receptor antagonist that completed Phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a 3,4-methylenedioxymethamphetamine R-enantiomer for the treatment of the core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Receive news and ratings for Mind Medicine (MindMed) every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com’s FREE daily newsletter.